Loading stock data…
EWTX
$30.61-0.35 (-1.13%)
Market ClosedLast close May 1
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Edgewise Therapeutics, Inc. in the Healthcare sector is trading at $30.61. The stock is currently near its 52-week high of $35.00, remaining 35.5% above its 200-day moving average. Technical signals show neutral RSI of 33 and bearish MACD signal, explaining why EWTX maintains its current momentum and trend strength. The Whystock Score of 70/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Oversold momentum (RSI 33) — potential for technical mean-reversion
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$30.61
Potential Upside
5%
Whystock Fair Value$32.14
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus12 analysts
Buy
Mean target$41.08+34.2%
Range$20.00 – $51.00
Fundamentals
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clini...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.35B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.25
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-28.86%
Volume
Today's trading volume
568,472
Recent News
Can Myqorzo Drive Growth for Cytokinetics Amid Competition?
CYTK enters the commercial stage with FDA-approved Myqorzo for oHCM, eyeing strong market share, but faces stiff competition and execution risks.
Edgewise Therapeutics, Inc. (EWTX) PT Increased to $45 at JPMorgan Amid Optimism on EDG-7500 Pipeline
We recently compiled a list of the 13 Best Stocks to Invest In on Robinhood for Beginners. Edgewise Therapeutics, Inc. is among the best Robinhood stocks. TheFly reported on March 17 that JPMorgan increased its price target for EWTX from $34 to $45 while keeping an Overweight rating on the stock. The firm also added […]
Why Edgewise Therapeutics Stock Topped the Market on Tuesday
One analyst tracking the biotech has become notably more bullish on its future.
Assessing Edgewise Therapeutics (EWTX) Valuation After Encouraging Long Term MESA Study Results
Why the latest MESA data matters for Edgewise Therapeutics stock Edgewise Therapeutics (EWTX) just released three and a half year data from its MESA open label extension study of sevasemten in Becker muscular dystrophy, highlighting stable motor function in a setting where decline is typically expected. See our latest analysis for Edgewise Therapeutics. Following the MESA update and recent conference appearances, Edgewise Therapeutics’ share price of $29.59 sits against a 90 day share price...
Why Edgewise Therapeutics (EWTX) Is Up 6.4% After Long-Term Sevasemten Becker Data - And What's Next
Edgewise Therapeutics recently presented long-term data from its MESA open-label extension study of investigational drug sevasemten in Becker muscular dystrophy, showing sustained stabilization of patient function over 3.5 years and a continued favorable safety profile. An unusually high 99% of eligible participants from prior sevasemten trials chose to enroll in MESA, underlining strong patient retention and interest in this potential first-in-class therapy for a disease with no approved...